^
    Back
    Association details:
    Biomarker:RUNX1-RUNX1T1 fusion
    Cancer:Acute Myelogenous Leukemia
    Regimen: (cytarabine + daunorubicin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Cell Int
    Title:

    Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients

    Published date:
    12/22/2018
    Excerpt:
    Patients with RUNX1-RUNX1T1 gene fusion were significantly more likely to achieve complete remission (CR) after DA60 induction therapy (p = 0.026), as were patients without the ASXL1 mutation (p = 0.007).
    DOI:
    10.1186/s12935-018-0716-7